Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Hypereosinophilic Syndromes
NCT00266565Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Dec 2001
- Primary completion
- Apr 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mepolizumab in hypereosinophilic syndrome (HES), eosinophilic gastroenteritis (EGE), eosinophilic granulomatosis with polyangiitis (EGPA), eosinophilic esophagitis (EoE), sponsored by Cincinnati Children's Hospital Medical Center. Started Dec 2001; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)eosinophilic gastroenteritis (EGE)eosinophilic granulomatosis with polyangiitis (EGPA)eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT00266565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266565.